OncoMatch/Clinical Trials/NCT04196257
BP1001-A in Patients With Advanced or Recurrent Solid Tumors
Is NCT04196257 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including BP1001-A (Liposomal Grb2 Antisense Oligonucleotide) and BP1001-A (Liposomal Grb2 Antisense Oligonucleotide) with paclitaxel for solid tumor, adult.
Treatment: BP1001-A (Liposomal Grb2 Antisense Oligonucleotide) · BP1001-A (Liposomal Grb2 Antisense Oligonucleotide) with paclitaxel — This is a phase I, open-label, study of BP1001-A in participants with advanced or recurrent solid tumors. The dose escalation phase will determine the safety and the maximum tolerated dose (MTD) or maximum administered dose (MAD) of BP1001-A as a single agent. After the MTD or MAD of BP1001-A is established, the dose expansion phase will commence and determine the safety, toxicity and response of BP1001-A in combination with paclitaxel.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Ovarian Cancer
Endometrial Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: bone marrow or hematopoietic stem cell transplant
Participants who had previous bone marrow or hematopoietic stem cell transplant
Lab requirements
Blood counts
HgB ≥ 9 g/dL, WBC ≥ 3,000/mcL, ANC ≥ 1,500/mcL, PLT ≥ 100,000/mcL
Kidney function
Serum creatinine < 1.5 x ULN or eGFR > 60 mL/min according to Cockcroft-Gault formula
Liver function
Total bilirubin within normal institutional limits, AST and ALT < 2.5 X institutional ULN
Participants must have adequate: Bone marrow function: HgB ≥ 9 g/dL, WBC ≥ 3,000/mcL, ANC ≥ 1,500/mcL, PLT ≥ 100,000/mcL; Hepatic function: Total bilirubin within normal institutional limits, AST and ALT < 2.5 X institutional ULN; Renal function: Serum creatinine < 1.5 x ULN or eGFR > 60 mL/min according to Cockcroft-Gault formula
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Holy Cross Hospital · Silver Spring, Maryland
- Karmanos Cancer Institute · Detroit, Michigan
- Mary Crowley Cancer Research · Dallas, Texas
- The University of Texas M.D. Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify